Tag: GlobeNewswire

Four winners each receive $45,000 and a full year of expert small-business services

KANSAS CITY, Mo., Oct. 29, 2026 (GLOBE NEWSWIRE) — The women building businesses across America are growing, but most are doing it alone. A survey¹ from H&R Block’s Fund Her Future grant program found that more than half launched their companies with no mentor and no support network, and that even as they embrace AI for everyday tasks, they draw a hard line at trusting it alone with their money. 

The findings, drawn from the Fund Her Future applicant data, center on a single theme: entrepreneurs want human connection. They want mentors and financial experts in their corner.

H&R Block today announced the four 2026 winners of Fund Her Future, an initiative that provides funding, financial services and programming to business owners. Kate H., Vermont; Yasmine B., California; DeJanae P., Texas; Harleen C., New York, were selected from more than 6,000 applicants and awarded a $45,000 grant and a full year of small-business services from H&R Block experts. These winners were selected because of the impact they are making on their communities, and their need for both financial support and business expertise to take their businesses to the next growth stage.

Beyond the four grant recipients, H&R Block is offering every applicant a $1,000 voucher to use toward any H&R Block small-business service. This includes tax preparation, bookkeeping, payroll, and totals more than $6.3 million in free services across all 6,379 applicants.

Programs like this, which invest in female business owners, are significant because women who want to start businesses face systemic barriers to capital, receiving just 2% of global venture funding.² Investing in female-owned businesses delivers outsized economic and social returns, as women consistently reinvest in their families and communities.

“Female small-business owners are growing, but too many are doing it without the capital, mentorship, and financial expertise they need to truly thrive,” said John Thompson, vice president of financial services and small business at H&R Block. “We go beyond funding, by providing the human support and professional services our research shows they want.” 

The data¹ makes clear why that human element matters: 

• They’re starting alone, without mentors: 54% of female business owners started their companies entirely on their own, with no mentor or support network. Only 12% had a formal mentor when launching. The gap is structural, not a lack of desire: 20% did not have a network of other entrepreneurs, and 15% did not know how to find a mentor. It is a theme that runs through the applicants.
• They want capital and financial expertise: 79% want access to capital and funding connections, the single most requested form of support. 62% want access to financial experts such as tax professionals and bookkeepers. Yet 52% currently manage their business finances entirely by hand, and 38% have never worked with a tax advisor, bookkeeper or payroll provider.
• They’re embracing AI, but not for finances: 79% of female business owners are already using or testing AI, and 77% expect it to help their business. While they trust AI for customer-facing tasks, they do not trust AI for financial projects. Just 7% trust AI for payroll. The finding underscores why Fund Her Future focuses on pairing grants with real people, and not just technology.

The economic backdrop gives the findings urgency with 64% of female business owners saying their business is growing and they anticipate expansion. Yet 66% reported prior-year revenue under $100,000, and one-third are pre-revenue or earning less than $25,000. Fund Her Future’s $45,000 grant gives winners the capital to bridge that gap, while the year of professional services addresses the human support the data shows they want most. 

2026 Fund Her Future Winners 

Kate H. is the founder of BirdieBlue, a brand that upcycles retired ski and snowboard gear into one-of-a-kind bags and accessories. By giving discarded mountain equipment a second life, Kate is building a sustainable business rooted in creativity and environmental stewardship. 

Yasmine B. is the founder of Hayati Goods, a modern Arabic food brand offering premium Palestinian za’atar spice blends. Her product brings authentic flavors and cultural heritage to kitchens across the country while celebrating the rich traditions of Palestinian cuisine. 

DeJanae P. is the founder of Dotted, a company offering non-toxic feminine care products and a reproductive health app designed for women navigating conditions like polyendocrine metabolic ovarian syndrome, formerly knowns as PCOS, and endometriosis. Her business is filling a critical gap in women’s health with products and technology built by and for the people who use them. 

Harleen C. is the founder of Harleen Kauer, a size-inclusive and ethically produced fashion brand creating modern Indo-Western clothing, from bridal lehengas to everyday kurtas. Her designs blend South Asian craftsmanship with contemporary silhouettes, offering women culturally resonant apparel for every occasion. 

For these four founders, the year ahead is about more than a grant check. It is about having someone to call when the books don’t balance, when a hiring decision looms, or when a product line is ready to scale. It is the human connection that 6,379 applicants said they wanted, and that Fund Her Future was built to provide. 

Visit Fund Her Future to learn more about the program and how to apply. 

About the Fund Her Future Application Survey 
H&R Block commissioned Hello Alice to collect data from the 2026 Fund Her Future applications, which included 6,379 applicants. 

About H&R Block 

H&R Block, Inc. (NYSE: HRB) provides help and inspires confidence in its clients and communities everywhere through global tax preparation services, financial products, and small business solutions. Named CNET’s Best Overall online tax service for 2026, the company blends digital innovation with human expertise and care as it helps people get the best outcome at tax time and manage their money better using its mobile banking app, Spruce. Through Block Advisors and Wave, the company helps small-business owners thrive with year-round bookkeeping, payroll, advisory, and payment processing solutions. For more information, visit H&R Block News. 

¹ 2026 Fund Her Future survey of 6,397 applicants through Hello Alice, commissioned by H&R Block.

² World Economic Forum, Empowering female founders: How we can narrow the gender gap in venture capital: https://www.weforum.org/stories/jobs-and-the-future-of-work/how-we-can-close-the-venture-capital-gender-gap, published Dec. 28,2023. 

Contact
Media Relations
Media Desk: mediadesk@hrblock.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/08beea2f-175a-4177-b064-efe1f0074c38

Noble Capital Markets, selected by NETSOL following an extensive evaluation of equity research providers, initiates coverage with an outperform rating and a $9.00 price target

ENCINO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-enabled solutions and services powering OEMs, dealerships and financial institutions to sell, finance and lease assets, today announced that Noble Capital Markets, Inc. has initiated company-sponsored equity research coverage of the company with an outperform rating and a $9.00 price target. NETSOL selected Noble following an extensive evaluation of equity research providers.

The initiation report, authored by Michael Kupinski, Director of Research and Senior Research Analyst, and Jacob Mutchler, Research Analyst, at Noble Capital Markets, Inc., points to NETSOL’s long-standing customer relationships and the ongoing replacement of aging lender architectures with the company’s Transcend Platform as key growth drivers, alongside the increasing shift toward subscription-based revenue as adoption of Transcend grows.

The coverage follows a record year for NETSOL. For fiscal 2026, the company reported revenue of $74.4 million, up 12.5% and above guidance, while operating income nearly doubled to $6.9 million and year-end cash rose 56.3% to $27.1 million.

“We’re building on a strong start to fiscal 2027 with a clear agenda ahead of us,” said Najeeb Ghauri, Founder and Chief Executive Officer of NETSOL Technologies, Inc. “As we work to make our performance more predictable and our story more visible to the market, broader research coverage matters. It gives investors a deeper, independent view of where NETSOL is headed and we look forward to the wider reach Noble’s coverage will bring.”

Noble’s full initiation report is available on Channelchek, Noble’s investor research platform:
https://www.channelchek.com/news-channel/netsol-technologies-inc-ntwk-transcending-to-the-next-stage-of-growth

About NETSOL Technologies
NETSOL Technologies delivers state-of-the-art solutions for asset finance, leasing and digital automotive retail, serving automotive and equipment OEMs, dealerships, auto captives and financial institutions across over 30 countries. Since its inception in 1997, NETSOL has been at the cutting edge of technology, pioneering innovations with its asset finance solutions, and today leverages advanced AI and cloud services to meet the complex needs of the global market. Renowned for its deep industry expertise, customer-centric approach and commitment to excellence, NETSOL fosters strong partnerships with its customers, ensuring their success in an ever-evolving landscape. With a rich history of innovation, ethical business practices and a focus on sustainability, NETSOL is dedicated to empowering businesses worldwide, securing its position as the trusted partner for leading firms around the globe.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the company’s products and services, expectations for future operations, and other statements that are not historical facts. These forward-looking statements may be identified by terminology such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “projects,” “targets,” and similar expressions. These statements are not guarantees of future performance and are subject to a number of risks, uncertainties, and assumptions that are difficult to predict. Factors that could cause actual results to differ materially include, but are not limited to, the timing of customer go-lives and contract renewals, the rate of adoption of AI-enabled product capabilities, foreign currency volatility, and other factors discussed in NETSOL’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. NETSOL undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investor Relations Contact:
Investor Relations
(818) 222-9195
investors@netsoltech.com

TORONTO, Oct. 29, 2026 (GLOBE NEWSWIRE) — Mink Ventures Corporation (TSXV:MINK) (“Mink” or the “Company“) today announced a non-brokered private placement for aggregate gross proceeds of up to $750,000 (the “Offering”). The Offering will consist of the sale of hard dollar units (the “HD Units”) of the Company at a price of $0.08 per HD Unit and flow-through units (the “FT Units”) of the Company at a price of $0.105 per FT Unit.

The Company plans to use the net proceeds raised from the sale of the HD Units and FT Units under the Offering for the exploration, drilling, and advancement of its 115 km² critical minerals project portfolio located within the prolific Timmins Camp. All programs are permitted and, subject to funding, include; conducting VTEM at its Montcalm nickel (Ni), copper (Cu), cobalt (Co) project, diamond drilling at its Warren Cu Ni project and the Rankin Cu Ni project and, in respect of the HD Unit proceeds, for general working capital purposes.

Each HD Unit will consist of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (“Warrant”). Each Warrant shall entitle the holder thereof to acquire one (1) common share of the Company for a period of thirty-six (36) months from the date of issuance at an exercise price of $0.16.

Each FT Unit will consist of one Common Share of the Company to be issued as a “flow-through share” (a “FT Share”) and one Common Share purchase warrant (“FT Warrant”). Each FT Warrant shall entitle the holder thereof to acquire one (1) common share of the Company for a period of thirty-six (36) months from the date of issuance at an exercise price of $0.16.

The FT Shares are to be issued as “flow-through shares” within the meaning of the Income Tax Act (Canada) (the “Tax Act”). An amount equal to the portion of the subscription price that is directly attributable to the consideration paid for the subscription and issuance of the FT Shares will be used to incur eligible resource exploration expenses which will qualify as (i) “Canadian exploration expenses” (as defined in the Tax Act), and (ii) “flow-through critical mineral mining expenditures” (as defined in subsection 127(9) of the Tax Act) (collectively, the “Qualifying Expenditures“). Qualifying Expenditures in an aggregate amount equal to the gross proceeds raised from the issuance of the FT Shares will be renounced to the initial purchasers of the FT Units with an effective date no later than December 31, 2026. The FT Warrants are not being issued as “flow-through shares” within the meaning of the Tax Act.

The securities issued under the Offering will be subject to a four-month and one day hold period and will not be sold in the United States. The Offering is subject to customary closing conditions including, but not limited to, receipt of approval of the TSX Venture Exchange (the “TSX-V”). The closing of the Offering may occur in one or more tranches, with the initial closing date of the Offering expected to occur on or around November 17, 2026 and is not subject to receipt of a minimum amount of gross proceeds. The Company may pay to certain introducing parties in respect of the Offering finder’s fees of up to 8% cash and non-transferable common share purchase warrants (“Finder Warrants”) to acquire that number of common shares equal to 8% of the number of HD Units and FT Units sold to investors so introduced, subject to compliance with applicable securities legislation and TSX-V policies. Each Finder Warrant shall entitle the holder thereof to acquire one (1) common share of the Company for a period of thirty-six (36) months from the date of issuance at an exercise price of $0.16.

About Mink Ventures Corporation:
Mink Ventures Corporation (TSXV:MINK) is a Canadian mineral exploration company exploring for critical minerals in Ontario, Canada. It has a prospective, nickel copper cobalt exploration portfolio, with its Montcalm project, which now covers approximately 100 km² adjacent to Glencore’s former Montcalm Mine with historical production of 3.93 million tonnes of ore grading 1.25% Ni, 0.67% Cu, and 0.051% Co (Ontario Geological Survey, Atkinson, 2010), as well as the expanded 11.3km² Warren Project, and its newly acquired Rankin Cu Ni project. These complementary nickel copper cobalt projects have excellent road access and infrastructure and are in close proximity to the Timmins Mining Camp. The Company has 41,672,296 common shares outstanding.

For further information about Mink Ventures Corporation please contact: Natasha Dixon, President & CEO, T: 250-882-5620 E: ndixon@minkventures.com or Kevin Filo, Director, T: 705-266-6818 or visit www.sedarplus.ca

Forward Looking Statements
This press release includes certain “forward-looking statements” under applicable Canadian securities legislation, including, but not limited to, statements with respect to the completion of the Offering, the proposed use of proceeds, and the exploration potential of the Company’s mineral properties. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Mink to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and factors include, among others: future prices and the supply of metals; the results of drilling; inability to raise the money necessary to incur the expenditures required to retain and advance the properties; environmental liabilities (known and unknown); general business, economic, competitive, political and social uncertainties; accidents, labour disputes and other risks of the mining industry; political instability, terrorism, insurrection or war; delays in obtaining governmental approvals; or failure to obtain regulatory approvals. For a more detailed discussion of such risks and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, refer to Mink’s filings with Canadian securities regulators available on SEDAR+ at www.sedarplus.ca.

Although Mink has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date of this news release and Mink disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

Topsoe continues to deliver engineering materials on schedule and on budget, 
advancing integrated FEED for production of sustainable aviation fuel,
renewable diesel and chemicals

HOUSTON, TX, Oct. 29, 2026 (GLOBE NEWSWIRE) — Abundia Global Impact Group, Inc. (NYSE American: AGIG) (“Abundia” or the “Company”), today provided an update on the previously announced engineering partnership with Topsoe using their HydroFlex^® upgrading technology for the Company’s first waste plastics-to-renewable fuels and chemicals facility at Cedar Port.

“We are pleased to provide shareholders with an update on the continued progress the Company has made over recent months on its engineering pack and to highlight Topsoe’s consistent delivery of critical information as we progress our Cedar Port facility toward commercialization,” said Joseph Gasik, Chief Operating Officer of Abundia. “Given Topsoe’s status and reputation within the industry, it should come as no surprise that they continue to deliver on schedule and within budget. We are now advancing the integration of technologies into a comprehensive FEED package. This progress reflects the disciplined execution of our development strategy and brings us another step closer to final investment approval (FIA).”

In March 2026, Abundia announced its partnership with Topsoe, a leading global provider of energy transition technologies, for the deployment of Topsoe’s HydroFlex^® upgrading technology as a key component of its planned Cedar Port facility. Building on that partnership, Abundia is pleased to report Topsoe has met all deliverables due to date, delivering critical engineering materials for its HydroFlex^® upgrading technology including the first issue of piping and instrumentation diagrams (P&IDs), material selection diagrams (MSDs), and equipment lists. Delivery of these materials represents an important advancement in the engineering design package and provides the technical foundation for progressing the full Front-End-Engineering Design (FEED) for Abundia’s integrated technology solution.

The planned 80,000-ton-per-annum facility is being designed to convert waste plastics into high-value, commercial-grade products, including sustainable aviation fuel (SAF), renewable diesel, and naphtha, by combining Alterra Energy’s proprietary plastics liquefaction technology with Topsoe’s HydroFlex^® upgrading platform. The integrated FEED program is being advanced with Burns & McDonnell as FEED engineering partner and Nexus PMG as Owner’s Engineer, providing the engineering foundation for subsequent project execution, procurement, and ultimately, final investment approval.

About Abundia Global Impact Group, Inc.

Abundia Global Impact Group, Inc. (NYSE American: AGIG) is a low-carbon energy company focused on converting waste into value. Headquartered in Houston, Texas, we are developing commercial-scale facilities that transform waste plastics and biomass into drop-in renewable fuels and low-carbon chemical feedstocks. Our flagship project at Cedar Port positions Abundia at the center of the Gulf Coast’s energy and chemical infrastructure, with access to feedstock supply chains, upgrading partners, and end markets.

For more information, please visit www.abundiaimpact.com.

Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information generally is accompanied by words such as “believe,” “may,” “will,” “could,” “intend,” “expect,” “plan,” “predict,” “potential” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this press release includes, but is not limited to, statements pertaining to the effects and anticipated effects of the Company’s inclusion in the Russell Microcap® Index. Actual results may differ materially from those indicated by these forward-looking statements as a result of a variety of factors, including, but not limited to: (i) the inherent uncertainties associated with business strategy and ongoing operations, the Company’s current liquidity positions, the Company’s ability to maintain the listing of its common stock on NYSE American, the Company’s ability to predict its rate of growth, and (ii) other risks as set forth from time to time in the Company’s filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are beyond the control of the Company.

With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing the Company’s business is disclosed in our Annual Report on Form 10-K and other filings with the SEC on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Investors:
CORE IR
IR@abundiaglobalimpactgroup.com

Memberships now available to all new and existing customers at $14 per month or $99 per year

Restaurant.com gift cards purchased by businesses now convert directly into membership, extending the Company’s corporate channel into continuing member relationships

Certificates purchased before the transition remain valid and do not expire

SCHAUMBURG, IL, Oct. 29, 2026 (GLOBE NEWSWIRE) — Giftify, Inc. (Nasdaq: GIFT) (the “Company”), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced that Restaurant.com, the nation’s largest restaurant-focused digital deals brand, has completed its transition to a membership-based model, effective October 27, 2026, as previously announced. Restaurant.com Membership is available now at $14 per month or $99 per year.

Active members can now access offers at participating restaurants without purchasing them individually, subject to each restaurant’s offer terms. Memberships are also available to be purchased as a gift.

Restaurant.com gift cards purchased by businesses for customer acquisition, loyalty programs, market research, employee recognition and customer promotions now convert directly into membership. Membership length will be determined by the denomination of the card provided to the recipient and will scale with value.

How businesses purchase is unchanged, but recipients now enter an ongoing membership relationship with Restaurant.com rather than a single transaction. For Giftify, this extends an established corporate channel into the membership base:

• business purchases now originate continuing member relationships;
• recipients receive access for the full membership term rather than a fixed amount of value to spend down; and
• Giftify gains an additional path to membership growth alongside direct consumer subscriptions.

Certificates purchased before the transition are unaffected and do not expire. Customers may continue to use them whether or not they become members or exchange an unused certificate for account points, which apply as a credit toward a membership. Redemption at participating restaurants is unchanged, and no change was required of restaurant partners.

“When we announced this plan, we said Restaurant.com would move to membership on October 27, and it did,” said Ketan Thakker, Chief Executive Officer of Giftify, Inc. “What we find most compelling is what membership does to the business side of Restaurant.com. Companies have been buying Restaurant.com for their customers and employees for years. Those purchases now begin a continuing relationship with a member rather than ending once the value is spent, which is a stronger benefit for our business customers and a different kind of asset for us.”

“Our goal on day one was that nothing our customers already held would be worth less, and nothing our restaurants do at the table would change,” said Thomas Butt, Chief Technology Officer of Giftify, Inc. “Certificates purchased before the transition keep working and do not expire, redemption works the way it always has, and members now have access to the offers at our participating restaurants for as long as they remain members. The transition was completed on schedule using our existing resources.”

Restaurant.com Membership is available now. For more information, visit www.restaurant.com.

About Giftify, Inc.

Giftify, Inc. (NASDAQ: GIFT) is a pioneer in the incentive and rewards industry with a focus on retail, dining & entertainment experiences, as the owner and operator of leading digital platforms, CardCash.com, Restaurant.com, and Takeout7.com. CardCash.com is a leading secondary gift card exchange platform, allowing consumers and retailers to realize value by buying and selling gift cards at various scales from over 1,100 retailers. Restaurant.com is the nation’s largest restaurant-focused digital deals brand, connecting digital consumers, businesses and communities by offering thousands of dining, retail and entertainment deal options nationwide at over 184,000 restaurants and retailers. Takeout7 is a restaurant technology company offering comprehensive online ordering solutions and AI-powered digital marketing services.

For more information, visit: www.giftifyinc.com, www.cardcash.com, www.restaurant.com, and www.takeout7.com.

Forward-Looking Statements

Press releases may include forward-looking statements. In particular, the words “believe,” “may,” “could,” “should,” “expect,” “anticipate,” “estimate,” “project,” “propose,” “plan,” “intend,” and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company. Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Giftify, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Giftify, Inc. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company’s ability to identify a suitable business model for the corporation.

Investor Contact:
IR@giftifyinc.com

PETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its third quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, November 11, 2026
Time:	8:30 AM Eastern Time
Conference Call:	https://register-conf.media-server.com/register/BIa693ec3496b1413b8682b952b2ff9e10
Webcast:	https://edge.media-server.com/mmc/p/rsj3o3mw

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com

ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026. Management will host a conference call and webcast at 4:30 PM EST that day to review the results and answer questions.

Participants may join by telephone or webcast using the details below.

Wednesday, November 4, 2026 at 4:30 pm EST
Participant Dial-In: 877-407-8835 / +1 201-689-8779
Conference ID #: 13763480
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=af6qsd3k

A replay of the webcast will be available in the Investors section of the Company’s website at investor.electrocore.com.

About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore^® non-invasive vagus nerve stimulation (nVNS) and Quell^® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in TJGC Group Limited (Nasdaq: TJGC) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in TJGC from 04:00:00 on October 15, 2026 to 23:59:00 on October 28, 2026. The last sale price of the company’s shares was $31.89. 

More information about the SEC’s order can be found at
https://www.sec.gov/files/litigation/suspensions/2026/34-106668.pdf.

Trading will remain halted until TJGC Group Limited has fully satisfied Nasdaq’s request for additional information.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotes^SM on the Nasdaq^® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

Nasdaq Contact:

Nasdaq MarketWatch
nasdaqmarketwatch@nasdaq.com

NDAQO

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY^® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY^® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com

Dr. Bender brings a proven track record in therapeutic development, company evolution, and strategic execution to help guide Diagonal’s continued pipeline progress

Diagonal is advancing a portfolio of multispecific clustering antibodies that restore normal receptor signaling to enable development of disease-modifying therapies, including DIAG723, currently in a Phase 1/2 clinical trial for Hereditary Hemorrhagic Telangiectasia

WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Diagonal Therapeutics, a clinical-stage biopharmaceutical company pioneering multispecific clustering antibodies to address the root causes of serious diseases, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., as Chair of its Board of Directors, succeeding Michael Gladstone, who will continue to serve on the Board. Dr. Bender brings over 20 years of drug development experience and company leadership to Diagonal Therapeutics.

“Jeremy is an accomplished biotechnology leader, who most recently steered Day One Biopharmaceuticals from an early clinical-stage biotech through its first successful commercial launch. We are thrilled to welcome him as Board Chair of Diagonal,” said Alex Lugovskoy, Ph.D., Founder and Chief Executive Officer of Diagonal. “Jeremy’s drug development experience in rare disease, deep operational expertise, and track record across strategic business development will be invaluable as we continue to advance clinical development of our lead program, DIAG723, which represents a potentially transformative, disease-modifying therapeutic for people impacted by hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). We’re extremely grateful to Michael Gladstone for his service as Diagonal’s founding Chair. Michael’s leadership has been fundamental in establishing Diagonal’s position as a leader in clustering antibody technology and driving the significant progress we have achieved across our pipeline. We look forward to his continued contributions as a Board member.”

Diagonal is currently enrolling patients in DIAMOND, a Phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial evaluating DIAG723 in people living with HHT, a rare, serious genetic vascular disorder. The DIAMOND trial will include a multidose Phase 2 cohort (Part C) in people with HHT and concomitant PAH to assess safety and exploratory effects on HHT- and pulmonary-related measures.

“Diagonal’s approach is straightforward and powerful – identify diseases caused by loss-of-function alterations and design antibody therapeutics that seek to activate and restore function through direct binding to altered proteins. This differs from other approaches, which aim to compensate indirectly for loss of function by inhibiting downstream components,” said Dr. Bender. “I look forward to working with Alex, the Diagonal management team, and my fellow board members as we harness this novel science to address the root cause of disease for patients in need.”

Dr. Bender most recently served as Chief Executive Officer, President and a member of the board of directors of Day One Biopharmaceuticals from 2020 to 2026 where he led the company’s evolution into a commercial-stage oncology company, including the approval and launch of OJEMDA^® for pediatric low-grade glioma and the company’s acquisition by Servier in 2026. Before Day One, he served as Vice President of Corporate Development at Gilead Sciences. Earlier in his career, Dr. Bender held executive leadership positions at Tizona Therapeutics (Chief Operating Officer), Sutro Biopharma (Chief Business Officer) and Allos Therapeutics (Vice President of Corporate Development), where he led corporate strategy, business development and operational execution. He began his career in the life sciences practice at Boston Consulting Group. Dr. Bender currently serves on the board of directors of Aura Biosciences, Bicara Therapeutics and Mereo BioPharma Group plc, and previously served on the board of Fusion Pharmaceuticals. He holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.

About Diagonal Therapeutics

Diagonal Therapeutics is a clinical-stage biopharmaceutical company pioneering multispecific clustering antibodies, a new class of biologics designed to address the root causes of serious diseases. Our clustering antibodies, derived from our proprietary DIAGONAL Product Engine, are designed to restore normal signaling by assembling receptors in the precise geometry required for activation in diseases that arise from deficient signaling pathways. Our lead product candidate, DIAG723, is a bispecific clustering antibody designed to restore normal activin receptor-like kinase 1 (ALK1) signaling, which is deficient in both hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). For more information, please visit www.diagonaltx.com.

Media Contact:
media@diagonaltx.com